Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 5/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23419080 | 0.90 | SSTR4 (0.41) | SSTR4EPHX2HSD11B1GAASLC22A12 | |
| SCHEMBL20193838 | 0.86 | P2RY1 (0.34) | SSTR4GRM4CXCR4 | |
| SCHEMBL20031355 | 0.86 | SSTR4 (0.42) | SSTR4EPHX2HSD11B1GAASLC22A12 | |
| SCHEMBL23419232 | 0.84 | SSTR4 (0.41) | SSTR4EPHX2HSD11B1GAASLC22A12 | |
| SCHEMBL18467354 | 0.79 | TLR8 (0.32) | SSTR4GRM4 | |
| SCHEMBL22140357 | 0.79 | GRM4 (0.32) | NFE2L2GRM4TRPV1 | |
| SCHEMBL29502462 | 0.79 | SSTR4 (0.47) | SSTR4EPHX2GAASLC22A12NFE2L2 | |
| SCHEMBL11955143 | 0.78 | SSTR4 (0.46) | SSTR4EPHX2HSD11B1GAASLC22A12 | |
| SCHEMBL22140280 | 0.77 | SSTR4 (0.40) | SSTR4 | |
| SCHEMBL23419175 | 0.77 | SSTR4 (0.39) | SSTR4EPHX2HSD11B1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381144-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN | SYNVENTA LLC (US) | 2023-11-30 | — | — | US | disclosed |
| US-20210155597-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN | SYNVENTA LLC | 2021-05-27 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381144-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN | TRPV1, OPRL1, ADRA2C | SSTR4 2201/4885EPHX2 781/4885HSD11B1 2428/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | SSTR4 1852/4885EPHX2 1070/4885HSD11B1 1304/4885 |
| US-20210155597-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN | TRPV1, OPRL1, OPRK1 | SSTR4 1126/4885EPHX2 948/4885HSD11B1 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.